ESP SEKK

Summary page of the EQA programme

Programmed death ligand 1 (PDL1)

This page provides the information about the programme in a nutshell. It is as concise as it can be.

Programme description

The programme is focused on external quality assessment of the PDL1 staining of 4 carcinoma types (subschemes TNBC, NSCLC, UC and HNSCC).
Complete description you can find in the EQA Plan 2022 (namely page 32).
Short description is available in the PDL1 2022 flyer.

Professional supervision

European Society of Pathology Quality Assurance Foundation
Barastraat 6, 1070 Brussels, Belgium
www.esp-pathology.org

EQA provider

SEKK s.r.o., EHK Division
ArnoŇ°ta z Pardubic 2605, 530 02 Pardubice, Czech Republic
www.sekk.cz

Participation in the year 2022

The laboratories from all countries are welcome to participate in PDL1 programme.

Very simple guide on how to order the Programmed death ligand 1 (PDL1) programme is available here.

Samples

The participants are free to order aby combination of the carcinoma types (subschemes).
Each participant examines 1 physical slide and 1 virtual slide for each carcinoma type they ordered.
The table shows complete collection of the samples:

Subscheme Set of the samples
Physical slide
unstained
Virtual slide
stained
1: TNBC PS VS
2: NSCLC PS VS
3: UC PS VS
4: HNSCC PS VS

Each slide bears one TMA section.
The columns (A to H) represent individual primary samples (carcinomas) different for each subscheme (thus column A in TNBC slide is a tissue different from the column A in other slides).
There are 3 cores of each primary sample in the TMA (rows 1 to 3).
Blackened cores represent tonsillars tissue (serve as block orientation element and staining quality indicator).

Results and evaluation

Each subscheme (carcinoma type) and each slide are evaluated separately.
The participants provide both quantitative (scores) and qualitative results (negative/positive) for each primary sample of each slide.
The evaluation is based on the qualitative results. Assigned values (AV), e.g. expected results (negative/positive) are determined in the network of 3 expert laboratories in Europe. From the point of view of the ISO 17043 it is CVE (consensus from experts) type of AV.
Each particular slide is evaluated as successful if the participant reports correct (i.e. equal to AV) results at least 3 out of 4 primary samples presented on the slide.

Last update: 13.12.2021